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Abstract
Background To define early versus late recurrence based on post-recurrence survival (PRS) among patients undergoing curative
resection for hepatocellular carcinoma (HCC).
Methods Patients who underwent curative-intent resection for HCC between 2000 and 2017 were identified from an interna-
tional multi-institutional database. The optimal cut-off time point to discriminate early versus late recurrence was determined
relative to PRS.
Results Among 1004 patients, 443 (44.1%) patients experienced recurrence with a median recurrence-free survival time of
12 months. A cut-off time point of 8 months was defined as the optimal threshold based on sensitivity analyses relative to
PRS for early (n = 165, 37.2%) versus late relapse (n = 278, 62.8%) (p = 0.008). Early recurrence was associated with worse PRS
(median PRS, 27.0 vs. 43.0 months, p = 0.019), as well as overall survival (OS) (median OS, 32.0 versus 74.0 months, p < 0.001)
versus late recurrence. In addition, patients who recurred early were more likely to recur at extra- ± intrahepatic (35.5% vs.
19.8%, p = 0.003) sites and were less likely to have the recurrence treated with curative intent (33.8% vs. 45.7%, p = 0.08).
Patients undergoing curative re-treatment of late recurrence had a comparable OS with patients who had no recurrence (median
OS, 139.0 vs. 140.0 months); patients with early recurrence had inferior OS after curative re-treatment versus patients with no
recurrence (median OS, 69.0 vs. 140.0 months, p = 0.036), yet still better than patients who received palliative treatment for early
recurrence (median OS, 69.0 vs. 21.0 months, p < 0.001).
Conclusions Eight months was identified as the cut-off value to differentiate early versus late recurrence. Curative-intent treat-
ment for recurrent intrahepatic tumors was associated with reasonable long-term outcomes.
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Introduction
Hepatocellular carcinoma (HCC) is a lethal malignancy with a
5-year survival of 20–40%. [1] Surgical resection remains the
mainstay curative treatment option for early stage HCC.
Long-term outcomes after curative resection of HCC are gen-
erally poor; however, due to a high incidence of recurrence, [2,
3] understanding the timing and patterns of recurrence is there-
fore important. In particular, timing of recurrence has a dem-
onstrated impact on prognosis, as early recurrence has been
associated with inferior clinical outcomes among patients un-
dergoing curative resection for HCC. [4] In particular, early
versus late recurrence has generally been classified using
2 years as the cut-off time point based on the assumed under-
lying mechanisms of relapse. [5, 6] Specifically, early recur-
rence within 2 years of surgery has generally been considered
to be recurrence of intrahepatic micro-metastasis, whereas late
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recurrence has been suggested to represent de novo tumor due
to multi-centric tumorigenesis. [7] This paradigm of recur-
rence has not been validated, and emerging genomic evidence
has suggested a more nuanced situation. For example, a recent
study by Ding and colleagues demonstrated that 33.3% of
HCC relapses within 2 years after resection were indeed
multi-centric HCC arising from an independent tumor lineage
compared with the initial tumor; in contrast, 36.4% of late
recurrent tumors appeared to derive from disseminated tumor
cells from the removed primary HCC. [8] Several other studies
have suggested that earlier relapse was associated with worse
prognosis after recurrence in HCC. [9, 10] From a clinical
standpoint relative to patient management, identifying patients
susceptible to early recurrence is important as these patients
may benefit from more intensive surveillance after surgery.
Post-recurrence survival (PRS) has been adopted as an in-
dicator to determine the optimal cut-off time point to discrim-
inate early versus late recurrence among patients undergoing
curative resection for pancreatic ductal adenocarcinoma. [11]
Up to now, a clear evidence-based definition of early versus
late recurrence has been lacking for patients undergoing re-
section of HCC. Therefore, the objective of the current study
was to establish a cut-off value to differentiate between early
versus late relapse relative to PRS, as well as identify potential
risk factors associated with early recurrence.
Methods
Study Cohort
Patients who underwent curative-intent resection for HCC be-
tween 2000 and 2018 were identified from an international
multi-institutional database. Patients were treated at 1 of the fol-
lowing 11 institutions: The Ohio State University Wexner
Medical Center, Columbus, OH, USA; The First Affiliated
Hospital of Xi’an Jiaotong University, Xi’an, China; University
of Verona, Verona, Italy; Hopedale San Raffaele, Milano, Italy;
Curry Cabral Hospital, Lisbon, Portugal; APHP, Beaumont
Hospital, Clichy, France; Westhead Hospital, Sydney, Australia;
Stanford University, Stanford, CA, USA; Funding Clinical
Institute, Bucharest, Romania; University of Ottawa, Ottawa,
Canada; The University of Sydney, School of Medicine,
Sydney, Australia. The study was approved by the Institutional
Review Boards of each participating institutions. All included
patients were treatment-naïve before surgical resection and no
patient received adjuvant therapy. Patients who died within
30 days after surgery were excluded (n=25, 2.4%).
Clinicopathological Variables
A standard datasheet was utilized to collect data at each insti-
tution. Demographic factors, including age, gender, status of
alcohol intake, diabetes mellitus, and hepatitis virus infection,
were collected from electronic records. Tumor-related charac-
teristics, including maximum tumor size, tumor number and
location, differentiation grade, presence of cirrhosis and mi-
crovascular invasion, underlying liver disease, liver capsule
involvement, and width of resection margin, were collected
based on final pathology. Liver function was classified using
the Child-Pugh classification, whereas tumor burden was de-
fined according to Barcelona Clinic Liver Cancer (BCLC)
staging. Surgical information, including surgical approach
(open versus laparoscopic), extent (major versus minor), and
type (anatomic versus non-anatomic) of resection, were col-
lected from the operation notes. Major hepatic resection re-
ferred to removal of three or more Cournand segments, while
anatomic hepatic resection was defined by the Brisbane 2000
nomenclature of liver anatomy. Adjuvant therapies were not
routinely adopted.
Primary outcomes were overall survival (OS) and
recurrence-free survival (RFS), both calculated from the date
of surgery. Recurrence was defined as identification of suspi-
cious imaging findings or biopsy-proven tumor. Recurrence
patterns including timing of recurrence, recurrence site
(intrahepatic, extrahepatic, or both), and tumor number and
size of recurrence as well as treatment approach for recurrent
lesions were recorded. Local recurrence referred to relapse
close to the resection margin of the liver tumor. Curative treat-
ment options for relapsed HCC included surgical resection
and ablation, while non-curative or palliative treatment includ-
ed intra-arterial therapies, systemic chemotherapies, and
targeted therapies, such as sorafenib. The adoption of curative
versus palliative treatment was largely based on the BCLC
stage of recurrent HCC. The secondary outcome was post-
recurrence survival (PRS). Postoperative morbidity was also
collected and graded as I-V according to the Clavien-Dindo
classification. [12]
Statistical Analysis
Clinicopathological variables were summarized using fre-
quencies plus percentages for categorical variables, while me-
dians and interquartile range (IQR) were used for continuous
covariates. Categorical covariates were compared with Chi-
square test or Fisher’s exact test and continuous variables with
Mann-WhitneyU test. The OS and PRSwere calculated using
the Kaplan-Meier method and differences were compared
using the log-rank test. Factors with a P value less than 0.1
on univariate analysis were subsequently included in multi-
variable Cox regression model to identify independent risk
factors associated with PRS. Similarly, associations between
potential risk factors and early or late recurrencewere assessed
by univariate logistic regression analysis. Variables with P
values less than 0.1 were selected as covariate to enter multi-
variable logistic regression model. All statistical analyses
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were performed using SPSS version 23.0 (IBM SPSS,




Among 1004 patients who underwent curative-intent liver re-
section for HCC, median age was 62 years (IQR, 53–71) and
the majority (n = 789, 78.6%) of patients were male. Most
individuals presented with Child-Pugh grade liver function
(n = 716, 93.8%) and had BCLC stage 0/A tumors (n = 800,
84.9%). Roughly, one-third (n = 291, 30.1%) of patients
underwent major resection; the majority (n = 799, 82.6%)
had an anatomical resection. An R0 margin was achieved in
the overwhelming majority of patients (n = 902, 90.0%)
(Table 1). On final pathology, microvascular invasion was
present in 32.5% (n = 284) of HCC tumors. A total of 411
(41.4%) patients experienced at least one complication after
surgery; a small subset (8.8%) of patients had severe (Clavien-
Dindo III–IV) complications.
Timing of Recurrence
With a median follow-up of 28.0 months (IQR 14.0–47.0),
443 (44.1%) patients experienced a recurrence following re-
section of the primary HCC. Cumulative recurrence at 1, 3,
and 5 years was 21.9%, 46.6%, and 58.0%, respectively
(Fig. 1). Perhaps not surprisingly, patients who developed
recurrence were more likely to have presented with advanced
tumor characteristics, such as large, multiple, and bilobar tu-
mors, poor differentiation, and microvascular invasion (all
p < 0.05, Table 1). Among the 443 individuals who developed
recurrence, the median time from initial surgery to recurrence
was 12.0 (IQR, 5.0–23.0) months.
Optimal cut-off value to differentiate early versus late
recurrence was determined by evaluating PRS at different
time points after surgery using 2-month intervals
(Table 2). Of note, 8 months after surgery was associated
with the largest difference in PRS among patients who
developed early versus late recurrence (median PRS, early
recurrence 27.0 vs. late recurrence 43.0 months, p =
0.008) (Fig. 2a). In turn, 8 months was used as the opti-
mal cut-off time for differentiating early versus late recur-
rence (Table 2). The cut-off time of 8 months was also
strongly associated with early versus late intrahepatic-
only recurrence (median PRS, early recurrence 27.0 vs.
late recurrence 43.0 months, p = 0.019) (Supplementary
Table 1). Moreover, patients who recurred within 8 months
after surgery had markedly worse OS versus patients who
experienced recurrence beyond 8 months after surgery
(median OS, early recurrence 32.0 versus late recurrence
74.0 months, p < 0.001) (Fig. 2b). In particular, patients
who recurred early had a 2-fold higher risk of death ver-
sus patients who recurred later after adjustment for tumor
characteristics, as well as treatment-related differences
(HR, 2.2; 95% CI, 1.3–3.6; p = 0.004) (Supplementary
Table 2).
Compared with late recurrence, early recurrence was
more likely to be associated with worse tumor character-
istics, such as high preoperative AFP (> 200 ng/ml), large
tumor size (> 5 cm), advanced BCLC stage, poor tumor
differentiation, as well as microvascular invasion (all
p < 0.05, Supplementary Table 3). These factors were also
associated with a higher risk of intrahepatic-only recur-
rence among patients with early versus late recurrence
(Supplementary Table 4). On multivariable analysis, in-
creased AFP level (> 200 ng/ml), large tumor size (>
5 cm), R1 margin, microvascular invasion, and poor tu-
mor differentiation were independent risk factors associ-
ated with early postoperative recurrence (all p < 0.05,
Table 4). In contrast, only tumor burden, including size
and number, was independently correlated with late recur-
rence beyond 8 months after primary surgery (all p < 0.05,
Table 4).
Recurrence Patterns and Treatment for Defined Early
and Later Recurrence
A majority of patients (n = 267, 74.2%) who recurred had
intrahepatic-only relapse, whereas 93 patients had
extrahepatic-only metastasis (n = 64, 17.8%) or extra- ±
intrahepatic recurrence (n = 29, 8.1%). Of note, recurrence
patterns and treatments were generally different among
patients with early or late recurrence. Specifically, patients
who recurred early within 8 months after primary surgery
were more likely to recur extra- ± intrahepatically versus
patients who recurred beyond 8 months after initial resec-
tion (35.5% vs. 19.8%, p = 0.003). With regard to
intrahepatic recurrence only, patients with early recur-
rence tended to have recurrent tumors that were larger in
size and were less frequently amenable to secondary cu-
ratively treatment options compared with patients who
experienced a late tumor recurrence (curative treatment
percentage, 33.8% vs. 45.7%, p = 0.080) (Table 3).
Among 231 patients who had detailed information on
treatment of intrahepatic-only recurrence, 96 (41.6%)
underwent curative resection/ablation, whereas 135
(58.4%) received only palliative treatments (Table 4). Of
note, the OS after initial resection among patients under-
going curative treatments for intrahepatic-only recurrence
was comparable to patients who had no recurrence during
the study period (median OS, 139.0 vs. 140.0 months, p =
0.561), yet better than patients treated with non-
127J Gastrointest Surg (2021) 25:125–133
curativepalliative options for the intrahepatic recurrence
(median OS, 139.0 vs. 43.0 months, p < 0.001) (Fig. 3a).
Interestingly, when stratified by recurrence time (early
versus late recurrence), patients who developed early
intrahepatic recurrence still had a worse OS even after
curative treatment versus patients who never recurred
(median OS, 69.0 vs. 140.0 months, p = 0.036), but OS
was better than patients who received palliative treatments
for early recurrence (median OS, 69.0 vs. 21.0 months,
p < 0.001) (Fig. 3b). In contrast, patients with late recur-
rence had a comparable OS after curative treatment versus
patients who had no recurrence (median OS, 139.0 vs.
140.0 months, p = 0.738) (Fig. 3c). Multivariable analysis
demonstrated that curative versus non-curative treatments
Table 1 Baseline demographics and clinicopathological variables of patients with versus without recurrence
Variables Overall (n = 1004) No recurrence (n = 561) Recurrence (n = 443) P
Age, years 0.830
≤ 60 454 (45.2%) 252 (44.9%) 202 (45.6%)
> 60 550 (54.8%) 309 (55.1%) 241 (54.4%)
Gender 0.495
Male 788 (78.6%) 436 (77.9%) 352 (79.6%)
Female 214 (21.4%) 214 (22.1%) 90 (20.4%)
Diabetes mellitus 259 (26.3%) 146 (26.4%) 113 (26.3%) 0.979
Chronic alcohol intake 186 (18.8%) 87 (19.9%) 99 (17.9%) 0.432
HBV infection 227 (25.8%) 130 (26.4%) 97 (25.1%) 0.648
HCV infection 212 (21.3%) 109 (19.5%) 103 (23.6%) 0.119
AFP, ng/ml < 0.001
≤ 400 655 (79.4%) 378 (84.8%) 277 (73.1%)
> 400 170 (20.6%) 68 (15.2%) 102 (26.9%)
Child-Pugh classification 0.526
A 716 (93.8%) 408 (93.4%) 308 (94.5%)
B 47 (6.2%) 29 (6.6%) 18 (5.5%)
Surgery types 0.008
Minimally invasive 275 (27.5%) 172 (30.9%) 103 (23.3%)
Open 724 (72.5%) 385 (69.1%) 339 (76.7%)
Extent of resection 0.082
Minor 676 (69.9%) 394 (72.7%) 282 (67.0%)
Major 291 (30.1%) 152 (27.8%) 139 (33.0%)
Type of resection 0.379
Anatomic 799 (82.6%) 446 (81.7%) 353 (83.8%)
Non-anatomic 168 (17.4%) 100 (18.3%) 68 (16.2%)
Maximum tumor size, cm < 0.001
≤ 5 524 (52.2%) 323 (57.6%) 201 (45.4%)
> 5 480 (47.8%) 238 (42.4%) 242 (54.6%)
Tumor number < 0.001
Single 885 (88.1%) 513 (91.4%) 372 (84.0%)
Multiple 119 (11.9%) 48 (8.6%) 71 (16.0%)
Tumor location 0.018
Unilobar 877 (92.2%) 504 (94.0%) 373 (89.9%)
Bilobar 74 (7.8%) 32 (6.0%) 42 (10.1%)
BCLC staging 0.002
0/A 800 (84.9%) 468 (88.1%) 332 (80.8%)
B/C 142 (15.1%) 63 (11.9%) 79 (19.2%)
Liver cirrhosis 439 (43.8%) 254 (45.4%) 185 (41.9%) 0.267
Grade < 0.001
Well to moderate 741 (77.4%) 434 (81.7%) 307 (72.1%)
Poor 216 (22.6%) 97 (18.3%) 119 (27.9%)
Microvascular invasion 284 (32.5%) 144 (28.9%) 140 (37.4%) 0.007
Capsule involvement 280 (36.6%) 158 (37.0%) 122 (36.1%) 0.796
Margin status 0.689
R0 902 (90.0%) 506 (90.4%) 396 (89.6%)
R1 100 (10.0%) 54 (9.6%) 46 (10.4%)
Postoperative complications 411 (41.4%) 222 (40.1%) 189 (43.0%) 0.372
Severe complications (III–IV) 87 (8.8%) 49 (8.9%) 38 (8.6%) 0.901
P values that are significant are in italics
BMI body mass index, ASA American Society of Anesthesiologists, NASH non-alcoholic steatohepatitis, PSC primary sclerosing cholangitis, PLT
platelet, ALT alanine aminotransferase, AST aspartate aminotransferase, AFP α-fetoprotein, BCLC Barcelona Clinic Liver Cancer
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of recurrence (HR 0.5, 95% CI 0.3–0.9) was independent-
ly associated with a favorable PRS (Supplementary
Table 2).
Discussion
Recurrence is common among patients with HCC after cura-
tive resection. [3, 7, 13–17] Data on timing of HCC recurrence,
as well as an evidence-based definition of early versus late
recurrence after curative resection, remain poorly defined.
While several investigators have proposed 24 months as a
cut-off value to differentiate early versus late recurrence, [3,
7] other studies adopted an earlier time point of 6 or 12months
as the cut-off. [14, 16] These past studies suffered from some
mythological weakness in that the proposed cut-off values
were not established based on a robust statistical assessment
of relevant clinical parameters. The current study was impor-
tant because we specifically examined multiple short-term in-
tervals (i.e., 2 months) to establish 8 months as the recurrence-
free interval to define early versus late recurrence relative to
PRS. Specifically, patients who developed early recurrence
within 8 months had markedly worse PRS, as well as OS
versus patients who recurred beyond 8 months after resection
of HCC. Of note, the characteristics of the initial HCC, as well
as recurrence patterns and post-recurrence treatments, were
different among patients who developed early versus late re-
currence. Specifically, patients who recurred within 8 months
were more likely to recur at an extra- ± intrahepatic site versus
patients who recurred beyond 8 months after the initial HCC
resection (35.5% vs. 19.8%, p = 0.003). Of note, patients who
developed a late recurrence had comparable OS after curative-
intent re-treatment of recurrence versus patients who had no
recurrence (median OS, 139.0 vs. 140.0 months, p = 0.738). In
contrast, patients who developed early intrahepatic recurrence
still had a worse OS even after curative re-treatments com-
pared with patients who did never recur (median OS, 69.0 vs.
140.0 months, p = 0.036).
Survival after recurrence likely reflects the malignant char-
acteristics of recurrent tumor and therefore data on early ver-
sus late recurrence may be important for prognostic purposes.
Fig. 1 Cumulative incidence of recurrence for HCC after curative
resection
Table 2 Defining cut-off














2 41.0 42.0 36.0 65.0 0.711
4 44.0 44.0 35.0 68.0 0.499
6 31.0 35.0 41.0 71.0 0.028
8 27.0 32.0 43.0 74.0 0.008
10 27.0 32.0 43.0 74.0 0.033
12 31.0 36.0 43.0 75.0 0.054
14 31.0 42.0 43.0 80.0 0.107
16 31.0 41.0 45.0 84.0 0.051
18 31.0 41.0 45.0 87.0 0.043
20 35.0 42.0 45.0 87.0 0.094
22 35.0 44.0 40.0 87.0 0.299
24 41.0 50.0 40.0 118.0 0.409
P values that are significant are in italics
PRS post-recurrence survival, OS overall survival
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Indeed, PRS has previously been adopted to differentiate early
versus late recurrence among patients with pancreatic ductal
adenocarcinoma. [11] In the current study, 8 months was uti-
lized as the optimal cut-off to differentiate early versus late
recurrence, as patients who recurred within 8 months after
surgery had markedly worse PRS versus patients who re-
curred beyond 8 months. Recently, Xing et al. had proposed
a similar cut-off of 8 months to define early recurrence in a
large series of patients from China. [17] The current study
builds on this previous work in that the data externally vali-
dated the 8-month cut-off using a large multi-center interna-
tional cohort of patients from mostly Western centers.
Interestingly, median PRS among patients with an early versus
late recurrence was 8.4 and 21.3 months, respectively, in the
study by Xing et al. In contrast, PRS was markedly better
among patients with early (27.0 months) or late (43.0 months)
in the current study. [17] The reason for the disparate results
was undoubtedly multifactorial and may have been related to
the predominance of HBV-related HCC (90.6%) and more
advanced tumor stage in the exclusively East Asian cohort
in the study by Xing et al. [17] To this point, the current
multi-institutional international cohort was mostly composed
of patients with Non-B Non-C HCC (52.9%) patients. Of
note, despite the differences in the baseline characteristics in
Fig. 2 Post-recurrence survival (a) and overall survival (b) among patients with early versus late recurrence
Table 3 Recurrence patterns of patients with early versus late recurrence
Variables Total (n = 443) Early recurrence (n = 165) Late recurrence (n = 278) P
Local recurrence 38 (10.6%) 15 (10.9%) 23 (10.4%) 0.872
Recurrence site 0.003
Intrahepatic 267 (74.2%) 89 (64.5%) 178 (80.2%)
Extrahepatic 64 (17.8%) 32 (23.2%) 32 (14.4%)
Both 29 (8.1%) 17 (12.3%) 12 (5.4%)
Intrahepatic-only recurrence
Number of recurrent lesions 0.682
Single 146 (60.6%) 47 (58.8%) 99 (61.5%)
Multiple 95 (39.4%) 33 (41.3%) 62 (38.5%)
Recurrent tumor size 2.2 ± 2.3 2.5 ± 2.3 2.1 ± 2.3 0.078
Treatment for recurrencea 0.080
Curative 96 (41.6%) 27 (33.8%) 69 (45.7%)
Non-curative 135 (58.4%) 53 (66.3%) 82 (54.3%)
P values that are significant are in italics
a Curative: resection or ablation; non-curative: chemotherapy, TACE or no treatment
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the two cohorts, the data in both studies demonstrated
8 months as the optimal cut-off to differentiate early versus
late recurrence.
Timing of recurrence likely indicates distinct relapse mech-
anisms and different prognoses. For example, early recurrence
is likely caused by dissemination of primary tumor and occult
metastasis before surgical resection. Thus, early-recurring tu-
mors have generally been more associated with aggressive
characteristics and worse outcomes. [15, 18] Risk stratification
to identify patients most at risk for early recurrence is clinical-
ly important in the postoperative setting to plan screening and
surveillance for recurrence. [5] In addition, several
Table 4 Multivariable logistic regression analysis of risk factors for early and late recurrence
Variables Univariate Multivariable
OR (95% CI) P OR (95% CI) P
Early recurrence
Age (years), > 60 vs. ≤ 60 1.0 (0.7–1.4) 0.986
AFP (ng/ml), > 200 vs. ≤ 200 3.5 (2.4–5.2) < 0.001 2.8 (1.8–4.4) < 0.001
Child-Pugh grade, B vs. A 0.7 (0.3–1.7) 0.409
Tumor number, multiple vs. single 1.9 (1.2–3.0) 0.007 1.3 (0.7–2.2) 0.439
Tumor size, > 5 vs. ≤ 5 2.0 (1.4–2.8) < 0.001 1.6 (1.0–2.6) 0.031
Cirrhosis, yes vs. no 1.2 (0.8–1.6) 0.417
Macrovascular invasion, yes vs. no 3.2 (1.8–5.9) < 0.001 1.2 (0.6–2.7) 0.572
Resection margin, R1 vs. R0 1.9 (1.2–3.1) 0.008 2.1 (1.1–3.8) 0.022
Liver capsule involvement, yes vs. no 1.0 (0.7–1.5) 0.841
Microvascular invasion, yes vs. no 3.2 (2.2–4.7) < 0.001 1.9 (1.2–3.0) 0.004
Tumor grade, poor vs. well/moderate 2.8 (1.9–4.1) < 0.001 2.0 (1.3–3.1) 0.002
Late recurrence
Age (years), > 60 vs. ≤ 60 1.0 (0.7–1.4) 0.921
AFP (ng/ml), > 200 vs. ≤ 200 1.1 (0.8–1.8) 0.496
Child-Pugh grade, B vs. A 0.9 (0.5–1.9) 0.880
Tumor number, multiple vs. single 1.7 (1.1–2.6) 0.027 1.6 (1.0–2.5) 0.035
Tumor size, > 5 vs. ≤ 5 1.4 (1.0–1.8) 0.031 1.4 (1.0–1.8) 0.040
Macrovascular invasion, yes vs. no 2.0 (0.9–4.6) 0.114
Cirrhosis, yes vs. no 1.1 (0.8–1.5) 0.470
Resection margin, R1 vs. R0 0.7 (0.4–1.1) 0.144
Liver capsule involvement, yes vs. no 0.9 (0.7–1.3) 0.657
Microvascular invasion, yes vs. no 0.9 (0.6–1.3) 0.544
Tumor grade, poor vs. well/moderate 1.1 (0.8–1.6) 0.544
P values that are significant are in italics
OS overall survival, ALT alanine aminotransferase, AST aspartate aminotransferase, AFP α-fetoprotein, BCLC Barcelona Clinic Liver Cancer, RFS
recurrence-free survival
Fig. 3 Overall survival according to treatment of recurrence for all patients (a) and the subgroup of patients with early (b) or late (c) recurrence
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investigators have even suggested that patients at risk of early
HCC recurrence may benefit from adjuvant treatments, in-
cluding intra-arterial therapy, as well as be screened for enroll-
ment in clinical trials given that there is no established stan-
dard adjuvant care for high-risk patients. [19] To this point, we
identified several tumor-specific factors including high AFP
level, large tumor size, microvascular invasion and poor dif-
ferentiation, as well as narrow surgical margins (< 1 mm) that
were independently associated with risk of early recurrence
within 8 months after initial surgery. In addition, early recur-
rence was more commonly noted to be at an extra-hepatic site
versus late recurrence. Collectively, the data suggest that pa-
tients with these features should be screened frequently in the
immediate post-operative period with a particular focus on
surveillance of extra-hepatic disease.
Data from the current study also supported the potential
benefit of re-treatment for recurrence relative to long-term
survival among patients with intrahepatic-only recurrence.
[18, 20, 21] A previous meta-analysis had reported median 5-
year OS after repeat resection, ablation, or transarterial
chemoembolization for recurrent HCC of 35.2% (22–84%)
and 48.3% (24–83%), 15.5% (0–56%), respectively. [2]
These data were consistent with data in the current study,
which noted a 5-year OS of 66.0% after repeat resection/
ablation versus only 37.0% after palliative treatment. Of note,
patients who underwent curative re-treatment of late recur-
rence had an even better long-term prognosis, which was even
comparable to OS of patients who had no recurrence (median
OS, 139.0 vs. 140.0 months). While OS following curative-
intent treatment of early recurrence was inferior to outcomes
among patients with no recurrence (median OS, 69.0 vs.
140.0 months, p = 0.036), prognosis was still markedly better
than patients who received palliative only treatments for early
recurrence (median OS, 69.0 vs. 21.0 months, p < 0.001).
While possible clinical differences and selection bias make
definitive conclusions not possible, the data did suggest that
repeat curative-intent surgery for well selected patients with
HCC recurrence may be warranted and provide a benefit.
The current study demonstrated that several clinicopatho-
logic factors were strongly associated with increased risk of
early recurrence. Identifying patients at high risk for early
relapse is of clinical significance. Specifically, these patients
may be appropriate to be enrolled in clinical trials to receive
neoadjuvant and/or adjuvant treatments. In addition, these
findings also suggest that perhaps a subset of patients at very
high risk of early recurrence may be better served with liver-
directed therapies other than surgery.Moreover, implementing
more stringent surveillance of disease within 8 months after
surgical resection in the subgroup of patients at high risk of
early recurrence may help in detection of early recurrence and
utilization of secondary curative treatments.
The present study should be interpreted in light of several
limitations. While the international multi-institutional-based
cohort increased sample size and generalizability, patient se-
lection, surgical procedures, as well as follow-up strategies
may have varied at the different centers. Detailed information
about the systemic and intra-arterial therapy was not available,
and therefore was not considered. In addition, some patients
with recurrence receivedmore than one treatment modality for
the recurrence. The current study considered the initial treat-
ment of the recurrence and based OS calculations from the
time of the first treatment of any recurrence.
In conclusion, a large number of patients with HCC re-
curred following curative-intent resection of HCC. Using a
large multi-center international cohort of patients, we identi-
fied 8 months as the cut-off value to differentiate early versus
late recurrence, which was consistent with data from a previ-
ous study based exclusively on Chinese patients. [17] Patients
who experienced an early recurrence within 8 months follow-
ing resection had a markedly shortened PRS versus patients
who recurred beyond 8 months after initial resection.
Curative-intent treatment for recurrent intrahepatic tumors
was associated with reasonable long-term outcomes and there-
fore should be considered for a select group of patients.
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